BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27994516)

  • 21. Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
    Keutgen XM; Kumar S; Gara SK; Boufraqech M; Agarwal S; Hruban RH; Nilubol N; Quezado M; Finney R; Cam M; Kebebew E
    Cancer; 2018 Feb; 124(3):636-647. PubMed ID: 29149451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.
    Sun C; Estrella JS; Whitley EM; Chau GP; Lozano G; Wasylishen AR
    Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35976056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
    Maxwell JE; Sherman SK; Howe JR
    Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
    de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
    Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches.
    Stevenson M; Lines KE; Thakker RV
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):525-548. PubMed ID: 30098714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.
    Speisky D; Duces A; Bièche I; Rebours V; Hammel P; Sauvanet A; Richard S; Bedossa P; Vidaud M; Murat A; Niccoli P; Scoazec JY; Ruszniewski P; Couvelard A;
    Clin Cancer Res; 2012 May; 18(10):2838-49. PubMed ID: 22461457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition.
    Tirosh A; Killian JK; Petersen D; Zhu YJ; Walker RL; Blau JE; Nilubol N; Patel D; Agarwal SK; Weinstein LS; Meltzer P; Kebebew E
    J Clin Endocrinol Metab; 2020 Oct; 105(10):3285-94. PubMed ID: 32706863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
    Périgny M; Hammel P; Corcos O; Larochelle O; Giraud S; Richard S; Sauvanet A; Belghiti J; Ruszniewski P; Bedossa P; Couvelard A
    Am J Surg Pathol; 2009 May; 33(5):739-48. PubMed ID: 19238077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
    Liu IH; Ford JM; Kunz PL
    Cancer Treat Rev; 2016 Mar; 44():1-9. PubMed ID: 26924193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.
    Soczomski P; Jurecka-Lubieniecka B; Krzywon A; Cortez AJ; Zgliczynski S; Rogozik N; Oczko-Wojciechowska M; Pawlaczek A; Bednarczuk T; Jarzab B
    Front Endocrinol (Lausanne); 2021; 12():681013. PubMed ID: 34122352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic Alterations of Both MEN1/ATRX and TP53/RB1 in Pancreatic Neuroendocrine Neoplasms.
    Zhang MY; He D; Zhang S; Liu JY
    Pancreas; 2022 Jul; 51(6):e91-e93. PubMed ID: 36206476
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
    Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
    Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors.
    Tirosh A; Kebebew E
    J Gastrointest Oncol; 2020 Jun; 11(3):567-577. PubMed ID: 32655936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
    Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
    Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL.
    Moore PS; Missiaglia E; Antonello D; Zamò A; Zamboni G; Corleto V; Falconi M; Scarpa A
    Genes Chromosomes Cancer; 2001 Oct; 32(2):177-81. PubMed ID: 11550286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
    Gleeson FC; Voss JS; Kipp BR; Kerr SE; Van Arnam JS; Mills JR; Marcou CA; Schneider AR; Tu ZJ; Henry MR; Levy MJ
    Oncotarget; 2017 Nov; 8(55):93464-93475. PubMed ID: 29212165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease.
    Libutti SK; Choyke PL; Alexander HR; Glenn G; Bartlett DL; Zbar B; Lubensky I; McKee SA; Maher ER; Linehan WM; Walther MM
    Surgery; 2000 Dec; 128(6):1022-7;discussion 1027-8. PubMed ID: 11114638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
    Scarpa A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.